我武生物：接受中泰证券等投资者调研

Group 1 - The core viewpoint of the news is that Iwubio (SZ 300357) is actively engaging with investors, as evidenced by a recent investor meeting where the company's chairman addressed questions [1] - Iwubio's revenue composition for the first half of 2025 shows that pharmaceutical manufacturing accounts for 99.59% of its total revenue, indicating a strong focus on this sector [2] - As of the latest report, Iwubio's market capitalization stands at 17.2 billion yuan, reflecting its valuation in the market [3] Group 2 - The Chinese innovative drug market has seen significant overseas licensing deals, totaling 80 billion USD this year, highlighting the growth potential in the biopharmaceutical sector [3] - There is a contrast between the hot secondary market for biopharmaceuticals and the cooling fundraising environment in the primary market, suggesting challenges ahead for new capital raising [3]